Kronos Bio, Inc. (KRON)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Kronos Bio, Inc. (KRON)
Company Performance

Current Price

as of Oct 16, 2024

$0.96

P/E Ratio

N/A

Market Cap

$58.18M

Description

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Metrics

Overview

  • HQSan Mateo, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerKRON
  • Price$0.965+0.52%

Trading Information

  • Market Cap$58.18M
  • Float65.45%
  • Average Daily Volume (1m)60,654
  • Average Daily Volume (3m)91,598
  • EPS-$1.75

Company

  • Revenue$8.41M
  • Rev Growth (1yr)44.21%
  • Net Income-$16.20M
  • Gross Margin84.38%
  • EBITDA Margin-633.37%
  • EBITDA-$17.03M
  • EV-$34.99M
  • EV/Revenue-4.16
  • P/EN/A
  • P/S6.90
  • P/B0.47
Documents
SEC Filings
8-K (2024-08-08)
8-K (2024-06-27)
8-K (2024-05-21)
8-K (2024-05-09)
8-K (2024-03-21)
8-K (2024-03-07)
8-K (2024-03-05)
8-K (2024-01-25)
8-K (2023-12-19)
8-K (2023-11-13)
8-K (2023-11-02)
8-K (2023-10-05)
8-K (2023-09-18)
8-K (2023-08-17)
8-K (2023-08-08)
8-K (2023-06-26)
8-K (2023-05-10)
8-K (2023-04-24)
8-K (2023-04-11)
8-K (2023-03-27)
8-K (2023-03-15)
8-K (2023-01-26)
8-K (2023-01-09)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-13)
10-Q (2023-08-08)
10-Q (2023-05-10)
10-K (2024-03-21)
10-K (2023-03-15)
Factset
Factset Business Description
Factset Street Account
Kronos Bio reports Q3 EPS ($0.54) vs FactSet ($0.51) [4 est, ($0.56)-(0.43)] ($0.78, 0.00) (2023-11-13T21:09:40Z)
Kronos Bio presents preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC ($1.18, +0.03) (2023-10-13T16:34:16Z)
Kronos Bio presents positive preliminary data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 KB-0742 study at the Connective Tissue Oncology Society Annual Meeting ($0.89, +0.05) (2023-11-02T16:06:16Z)
Kronos Bio discloses abstract on first-in-human study of CDK9 Inhibitor KB-0742 - 8-K ($1.26, 0.00) (2023-10-05T12:07:25Z)
Kronos Bio announces plan to optimize resource allocation, restructure, and contain costs ($0.80, 0.00) (2023-11-02T20:47:04Z)
Kronos Bio announces pipeline update and p300 KAT inhibitor development candidate ($1.46, 0.00) (2023-12-19T14:35:34Z)
Insider transaction: Kronos Bio President & CEO Norbert Bischofberger discloses purchase of 1.7M shares ($1.11, 0.00) (2023-11-17T22:56:52Z)